Related references
Note: Only part of the references are listed.Proteasome Activators
Beth M. Stadtmueller et al.
MOLECULAR CELL (2011)
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
Dharminder Chauhan et al.
BLOOD (2010)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma
G. Wei Xu et al.
BLOOD (2010)
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model
Ajita V. Singh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Erik Kupperman et al.
CANCER RESEARCH (2010)
Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome-ATPase interactions
Yadong Yu et al.
EMBO JOURNAL (2010)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance
Xiaoming Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Characterization of bortezomib-adapted I-45 mesothelioma cells
Lidong Zhang et al.
MOLECULAR CANCER (2010)
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial
A. Dispenzieri et al.
LEUKEMIA (2010)
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
S. K. Kumar et al.
LEUKEMIA (2010)
Assembly, structure, and function of the 26S proteasome
Lynn Bedford et al.
TRENDS IN CELL BIOLOGY (2010)
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Deborah J. Kuhn et al.
BLOOD (2009)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
Shuqing Lue et al.
EXPERIMENTAL HEMATOLOGY (2009)
Metal Ionophores - An Emerging Class of Anticancer Drugs
Wei-Qun Ding et al.
IUBMB LIFE (2009)
Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
Han-Jie Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma
X. Mao et al.
LEUKEMIA (2009)
TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors
Remco Sprangers et al.
BIOCHEMISTRY (2008)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits
Antonia Busse et al.
CANCER (2008)
Histione H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation
Wenlai Zhou et al.
MOLECULAR CELL (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
Roberto Piva et al.
BLOOD (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
Claudia P. Miller et al.
BLOOD (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging
Jianping Jin et al.
NATURE (2007)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts
Di Chen et al.
CANCER RESEARCH (2007)
20S proteasome and its inhibitors: Crystallographic knowledge for drug development
Ljudmila Borissenko et al.
CHEMICAL REVIEWS (2007)
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
Mark J. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Regulation of DNA repair by ubiquitylation
TT Huang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis
M Bazzaro et al.
CANCER RESEARCH (2006)
Regulation of monoubiquitinated PCNA by DUB autocleavage
TT Huang et al.
NATURE CELL BIOLOGY (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib
M Politou et al.
LEUKEMIA RESEARCH (2006)
Genome analysis and functional characterization of the E2 and RING-type E3 ligase ubiquitination enzymes of Arabidopsis
E Kraft et al.
PLANT PHYSIOLOGY (2005)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1
LM Lois et al.
EMBO JOURNAL (2005)
The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway
SMB Nijman et al.
MOLECULAR CELL (2005)
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells
KG Daniel et al.
BREAST CANCER RESEARCH (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban
M Konagaya et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2004)
Phase I study of bortezomib in refractory or relapsed acute leukemias
J Cortes et al.
CLINICAL CANCER RESEARCH (2004)
Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity
M Gaczynska et al.
BIOCHEMISTRY (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8
H Walden et al.
NATURE (2003)
The structure of the APPBP1-UBA3-NEDD8-ATP complex reveals the basis for selective ubiquitin-like protein activation by an E1
H Walden et al.
MOLECULAR CELL (2003)
Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora
RH Feling et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2003)
Concentrations of Fe, Cu and Zn in breast tissue: a synchrotron XRF study
K Geraki et al.
PHYSICS IN MEDICINE AND BIOLOGY (2002)
The structure of the mammalian 20S proteasome at 2.75 Å resolution
M Unno et al.
STRUCTURE (2002)
A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins
S Polo et al.
NATURE (2002)
A gated channel into the proteasome core particle
M Groll et al.
NATURE STRUCTURAL BIOLOGY (2000)
PR39, a peptide regulator of angiogenesis
J Li et al.
NATURE MEDICINE (2000)
Share Paper
